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Abstract
Hepatitis E virus (HEV) as an emerging zoonotic pathogen causes a major public health issue. Transmission from
domestic, wildlife and zoo animals to human has been widely reported. Whether pets also serve as reservoirs
remains an intriguing question. In this study, we found the sero-positive rates of HEV-specific antibodies in pet
dogs, cats and horses of 18.52% (30/162), 14.89% (7/47) and 18.18% (4/22) in the Netherlands. Although HEV viral
RNA was not detected in these animals, we have demonstrated that dog liver cells are susceptible to HEV infection
in vitro. These results call more attention to address the potential role of pets in the zoonotic transmission of HEV.
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Introduction
Hepatitis E virus (HEV) as a single-stranded positive-
sense RNA virus belongs to the Hepeviridae family and
is the causative agent for hepatitis [1]. Although there is
only one serotype, HEV strains are currently classified
into eight genotypes, of which four are the most import-
ant for human diseases. Genotype 1 and 2 are known to
infect human only, and mainly cause acute infection. On
the contrary, genotype 3 and 4 are well-recognized
zoonotic strains circulating among a broad spectrum of
animal species. Both domesticated and wild animals have
been recognized as potential reservoirs [2–4]. Indeed,
evidence has indicated that companion animals includ-
ing dogs and cats might be accidental hosts for HEV and
might constitute a source for HEV transmission to
human [5, 6]. A very recent study in South Korea has
reported the seroprevalence of HEV in pet dogs and pet
veterinarians of 28.2 and 5.0%, respectively [7]. Genotype
3 strains have also been identified in horses, and ap-
peared closely related to human isolates from the same
region [8].
In Europe, the increase in autochthonous cases of
hepatitis E mainly attributes to the zoonotic transmis-
sion of genotype 3 HEV. Although consumption of raw
or undercooked pork meat and liver has been recognized
as the common source of infection, other unknown
transmission routes may also be important in contribut-
ing to this growing public health burden in Europe [9].
Therefore, we aimed to investigated HEV seroprevalence
among pet dogs, cats and horses in the Netherlands.
Furthermore, we have evaluated the permissiveness of
canine liver cells to human genotype 3 HEV in experi-
mental settings.
Materials and methods
Serum samples from pet dog (n = 162), cat (n = 47) and
horse (n = 22) were collected from May to September in
2017, and fecal samples from pet dog (n = 19) were
collected in September of 2017, at the Department of
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Samples were stored at − 80 °C until analysis.
Total HEV-specific antibodies in sera were detected by
the species-independent double-antigen sandwich ELISA
(WANTAI HEV-Ab #WE-7396) according to the manu-
facturer’s instructions. A SYBR green-based quantitative
real-time PCR (qRT-PCR) array was used to quantify
HEV RNA in the serum and fecal samples (primers are
listed in Supplementary table 1). All anti-HEV antibody
positive serum samples were tested individually, whereas
every ten negative samples were pooled with 30 μL of
each for HEV RNA detection. Fecal samples were tested
individually. RNA was isolated with a Macherey-Nucleo
Spin RNA kit. cDNA was synthesized from total RNA
using a cDNA Synthesis Kit (TAKARA BIO INC). The
cDNA was amplified for 50 cycles and quantified accord-
ing to the manufacturer’s instructions.
The human hepatoma cell line (Huh7.5) and dog liver
cancer cell line (BDE) [10] were cultured in DMEM
supplemented with 10% volume/volume (v/v) fetal calf
serum, 100 IU/mL penicillin and 100 μg/mL strepto-
mycin. A plasmid construct containing the full-length
HEV genome (genotype 3 Kernow-C1 p6 clone, GenBank
accession number JQ679013) or a construct containing
subgenomic HEV sequence in which ORF2 (Open Read-
ing Frame 2) was replaced by a Gaussia luciferase reporter
gene (p6-Luc) was used to generate HEV genomic RNA
by using the Ambion mMESSAGE nMACHINE in vitro
RNA transcription kit. Cells were electroporated with p6
full-length HEV RNA or p6-Luc subgenomic RNA to
generate infection and luciferase-based replicon models,
respectively. For the p6 infectious model, qRT-PCR was
used to quantify genomic RNA. An HEV plasmid-based
standard curve was constructed as a reference to as-
sess and quantify the copy number of HEV genome
(Supplementary Figure 1). HEV ORF2 protein was de-
tected by immunofluorescent staining. For the p6-Luc
replicon model, the activity of secreted luciferase in
the cell culture medium was measured by the BioLux
Gaussia Luciferase Flex Assay Kit (New England Biolabs,
MA) and quantified with a LumiStar Optima lumines-
cence counter (BMG LabTech, Offenburg, Germany).
Results and discussion
To investigate the prevalence of HEV in domestic pets
in the Netherlands, we have collected serum samples
from 162 dogs, we found that 18.52% (30/162) dogs were
positive for anti-HEV antibodies in serum. Literature
data on the seroprevalence of HEV antibodies in dogs
ranges from 0.8% in UK [11], 28.2% in South Korea [7],
13.54 to 36.55% in different regions of China [6, 12–14],
and 56.6% in Germany [15]. Genomic HEV RNA was
not detectable in these serum samples by qRT-PCR.
From the 162 dogs, there were 19 fecal samples avail-
able. Although 4 of 19 matched sera were positive for
anti-HEV antibodies, HEV RNA was not detected in any
of the fecal samples (Table 1). Dogs experimentally in-
fected with swine HEV have been shown to induce an
antibody response but no HEV RNA was detected in
serum post-inoculation [16]. HEV RNA was not detect-
able in any of those previous studies as well as in our
study.
We next investigated whether canine liver cells are
permissive for HEV infection in cell culture models.
Electroporation of subgenomic HEV RNA (p6-Luc;
human genotype 3 strain) into the BDE dog liver cell
line resulted in production of secreted luciferase as mon-
itored up to 21 days. Although the luciferase activity was
gradually decreased overtime and the overall activity is
lower compared to that in the human hepatoma Huh7.5
cells, these results indicate that dog liver cells can sup-
port HEV replication (Fig. 1a). Of note, Huh7.5 cells are
highly permissive and widely used for modeling HEV in-
fection in vitro [17]. Consistently, electroporation of the
full-length genomic HEV RNA into BDE cells resulted
in long-term production of HEV in the supernatant as
monitored over 45 consecutive days (Fig. 1b). Further-
more, HEV ORF2 protein was expressed in these cells
detected by immunofluorescent staining (Fig. 1c).
We confirmed the anti-HEV activity of interferon-α
and ribavirin in Huh7.5 based HEV subgenomic and infec-
tious models (Supplementary Figure 2). Consistently, we
found that interferon-α effectively inhibited viral replica-
tion in BDE cells in both HEV models. The inhibitory
effects of ribavirin were potent in the subgenomic model,
but only effective at later time points (72 and 96 h) in the
infectious model (Fig. 1d). To verify whether produced
HEV are infectious, we collected supernatant from full-
length HEV RNA electroporated BDE cells with a HEV
genomic titer of 7.4 × 106 copies/mL and inoculated the
naïve BDE and Huh7.5 cells. We have demonstrated the
replication of HEV in both cell lines by quantification of
intracellular viral RNA (Fig. 1e) and immunofluorescent
staining of ORF2 protein (Supplementary Figure 3). This
also support that dog liver cells are permissive for the
entry of infectious HEV particles. Collectively, we have
Table 1 Detection of anti-HEV total antibodies by ELISA and
HEV RNA by PCR in serum and fecal samples collected from pet
dogs, cats and horses
Animal Species
(Serum)
ELISA (Total antibodies) HEV RNA
Positive/total (%) Positive/total (%)
Dog 30/162 (18.52) 0/162 (0)
Cat 7/47 (14.89) 0/47 (0)
Horse 4/22 (18.18) 0/22 (0)
Remark: HEV RNA in dog fecal samples; positive /total (%): 0/19 (0)
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Fig. 1 Canine liver cells support the full life-cycle of HEV infection. a, In BDE cells upon electroporation of the subgenomic HEV RNA with
luciferase reporter, HEV luciferase activity (representing virus replication level) was sustained for 21 days (mean ± SEM; n = 2). b, Upon
electroporation of the full-length genomic HEV RNA, BDE cells support long-term production of HEV in the medium for 45 days as quantification
of the viral genome by qRT-PCR and calculated as copy numbers (mean ± SEM; n = 2). c. Immunofluorescence staining of viral protein ORF2 (red)
in BDE cells. BDE-HEV cells incubated with the matched IgG control antibody serves as negative control, and HEV infected Huh7.5 cells serves as
positive control. DAPI (blue) was applied to visualize nuclei. (40× oil immersion objective; Scale bar, 200 μm). d, Anti-HEV activity of ribavirin and
interferon-α (IFN-α) in BDE cell based HEV models. Treatment of ribavirin or IFN-α for 24, 48, 72 or 96 h in the subgenomic model determined by
luciferase activity (mean ± SEM, n = 5. CTR, non-treatment control.), and in the infectious model determined by viral RNA (mean ± SEM, n = 4. CTR,
non-treatment control). *P < .05; **P < .001; ***P < .0001. e, BDE and Huh7.5 cells are permissive for secondary infection with inoculation of BDE
cells produced HEV viral particles as determined by qRT-PCR at 24, 48, 72 and 96 h post-inoculation (mean ± SEM; n = 2). The level of HEV
infection in Huh7.5 cells for 24 h serves as 1. GAPDH serves as a reference gene
Li et al. Irish Veterinary Journal            (2020) 73:6 Page 3 of 5
demonstrated that dog liver cells are permissive for hu-
man genotype 3 HEV, and support the full life-cycle of the
infection. Nevertheless, this human HEV strain is a cell
culture adapted strain that may not fully recapitulate the
clinical strains.
In addition, we found that 14.89% (7/47) of cats and
18.18% (4/22) of horses were positive for anti-HEV anti-
bodies. The anti-HEV seroprevalence rates in cats have
been reported to be 6.28% in China [12], 8.1% in Korea
[16], and 33% in Japan [5], but our data are the first to
come from Europe. Up to date, only two studies have in-
vestigated the prevalence of HEV infection in horses. 13%
(26/200) of anti-HEV antibody positivity and 2% (4/200)
HEV RNA positivity were found in work horses in Egypt
[8]. In a study from China, 16.3% (8/49) of horses were
found to be positive of anti-HEV antibody and HEV RNA
was detected in one horse [14]. Overall, our data suggest
that companion animals are frequently exposed to HEV
and thus potentially infectious for humans in close contact
with these animals. In apparent agreement, when compar-
ing with the general population, veterinarians and dog
farm staff who are frequently exposed to dogs have signifi-
cantly higher rates of anti-HEV antibody positivity [6].
In summary, this study has pioneered the survey of
HEV infection in pets in the Netherlands. We found sub-
stantial positive rates of anti-HEV antibodies in dogs, cats
and horses, but viral RNA was not detected. However, the
sample size was relatively small and may not be fully rep-
resentative for the country. In addition, dietary factors
may differ between countries with different input of raw
animal meat in dog and cat food. Importantly, our experi-
mentation in cell culture has demonstrated that dog liver
cells are permissive for human genotype 3 HEV infection.
Thus, further investigation into the prevalence and the po-
tential of zoonotic transmission from pets is urged.
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Additional file 1: Table S1. qRT-PCR primer sequences. Figure S1.
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(CT) value. Figure S2. Potent anti-HEV activity of ribavirin and interferon-
α (IFN-α) in Huh7.5 cell model. Treatment of ribavirin or IFN-α for 24, 48,
72 or 96 h in the subgenomic model determined by luciferase activity
(mean ± SEM, n = 5. CTR, non-treatment control.), and in the infectious
model determined by viral RNA (mean ± SEM, n = 4. CTR, non-treatment
control). *P < .05; **P < .001; ***P < .0001. Figure S3. Immunofluorescence
staining of viral protein ORF2 (red) in BDE cells, upon infection of 24 h,
48 h, 72 h and 96 h. BDE-HEV cells incubated with the matched IgG con-
trol antibody serves as negative control, and HEV infected Huh7.5 cells
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